Michael Kiefer serves as Director of Research & Development at DiamiR. Dr. Kiefer has extensive molecular biology and assay development experience working primarily in start-up and early development biotech companies. From 2001 to 2016, Dr. Kiefer worked as a Senior Scientist at Genomic Health Inc. He led a research group that pioneered the development of a prototype diagnostic assay for predicting breast cancer recurrence, Oncotype DX. Prior to Genomic Health, 1993-1998, Dr. Kiefer served as a Senior Scientist, Director of Molecular Biology and Vice President of Molecular Biology at LXR Biotechnology Inc., where his group discovered BAK, a gene important in the regulation of cell death. Dr. Kiefer also served as a Research Scientist and Senior Scientist at Chiron Corp., 1987-1993, developing molecular cloning methods to facilitate the isolation of novel bone growth factors. Dr. Kiefer has published 74 articles and has 32 issued patents. He has a Ph.D. in Biochemistry and Biophysics and a B.S. in Zoology, both from the University of California, Davis.